Selank: The Russian Anxiolytic Peptide That Doesn't Sedate
Selank is a 7-amino-acid tuftsin analog used in Russia for anxiety. It modulates GABA and serotonin without benzodiazepine-like sedation. The honest evidence and protocol.
In 2008, Anatoly Zozulya and colleagues at the V. P. Serbsky Center in Moscow published a clinical trial in Bulletin of Experimental Biology and Medicine comparing a peptide called selank to medazepam — a benzodiazepine — in patients with generalized anxiety disorder and neurasthenia. Across the treatment period, selank produced anxiety reduction comparable to medazepam. The differences were in what selank did not do. No sedation. No cognitive impairment. No withdrawal syndrome after discontinuation. No documented dependence.
Selank had been developed at the Institute of Molecular Genetics in Moscow in the 1990s, modeled on tuftsin — a short peptide derived from the heavy chain of immunoglobulin G. Tuftsin's natural biological role is in immune modulation; the synthetic modification produced central nervous system effects. By the mid-2000s, selank was registered as a medication in Russia for anxiety disorders.
Outside Russia, selank exists where most Russian peptides exist: a research-chemical category in Western markets, an FDA-not-approved status everywhere outside the post-Soviet space, and a user base that ranges from sophisticated nootropic enthusiasts to anxiety patients self-medicating around prescription gaps. The honest framing matters. Selank has genuine Russian clinical data. It does not have Western regulatory recognition. These two facts coexist.
The Molecule and the Mechanism
Selank is the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues are tuftsin (Thr-Lys-Pro-Arg). The C-terminal Pro-Gly-Pro is the same stabilization sequence used in semax — it slows proteolytic degradation and extends biological half-life.
Mechanistically, selank operates through several systems:
GABA-A receptor modulation — Volkova and colleagues (2016) demonstrated that selank administration alters expression of GABAergic genes in the brain. The modulation is not direct binding at the benzodiazepine site of the GABA-A receptor (which would produce sedation); it appears to be an indirect modulatory effect that enhances GABA signaling without the receptor occupancy pattern of benzodiazepines.
Serotonergic modulation — selank affects serotonin metabolism and turnover, contributing to the anxiolytic effect through pathways distinct from SSRI mechanisms.
Enkephalin pathway interactions — preclinical work has shown that selank prolongs the half-life of endogenous enkephalins, which has implications for both stress modulation and pain perception. This is part of why selank does not produce the cognitive dulling typical of benzodiazepines — the system being modulated is different.
BDNF and neurotrophic effects — Inozemtseva and colleagues (2008) showed that intranasal selank upregulates BDNF expression in rat hippocampus, similar to semax. The BDNF effect is part of why selank is often described as cognitively activating rather than cognitively dulling, despite its anxiolytic action.
Immune modulation — the tuftsin lineage gives selank some peripheral immune effects, including reported antiviral activity in Russian studies. This is the most disputed mechanism in the Western evaluation of the peptide.
The mechanism summary: selank reduces anxiety through GABA-A and serotonergic modulation without benzodiazepine receptor binding, while simultaneously providing BDNF-mediated neurotrophic support. The combination produces the unusual profile — calm without sedation, anxiolysis without cognitive impairment.
The Clinical Data — Russian, Limited, Real
The Zozulya 2008 trial is the canonical clinical citation. In a Russian clinical population with diagnosed generalized anxiety disorder and neurasthenia, selank produced anxiety reduction over 14 days at intranasal doses of 900 mcg/day total. Comparison with medazepam showed similar efficacy on anxiety scales. The selank group did not show the sedation, cognitive slowing, or dependence-related discontinuation effects seen in the benzodiazepine group.
This trial is the strongest clinical evidence. It is also methodologically limited by current Western standards — the sample size was modest, the blinding methodology is not described in detail in the English-language extracts, and the replication has been entirely within the Russian research network.
Kozlovskaya and colleagues (2003) summarized the broader behavioral pharmacology in rodent models — selank reduces anxiety-like behavior in open field, elevated plus maze, and conflict tests without sedation or motor impairment. The animal data is consistent.
Semenova and colleagues (2009) demonstrated cognitive support effects in a model of cholinergic neuronal damage — selank preserved learning and memory performance after lesion of the basal nucleus of Meynert in rats. This contributes to the cognitive-supportive framing of the peptide.
The honest summary: selank has Russian clinical evidence in anxiety disorders and consistent animal evidence for non-sedating anxiolysis with cognitive preservation. It does not have Western confirmatory trials, large-scale safety data outside Russian populations, or long-term outcome studies. The position is similar to semax — discussed in semax-peptide-benefits — but with the anxiety indication being the primary use case.
The Anxiety Conversation — What Selank Is Actually Useful For
The anxiety treatment landscape in 2026 is bifurcated. On one side, prescription pharmacotherapy: SSRIs (effective for chronic anxiety, weeks-to-effect, broad side-effect profile), SNRIs (similar), benzodiazepines (effective acutely, addictive long-term), buspirone (modest effect), and beta-blockers for performance anxiety. On the other side, behavioral approaches: cognitive-behavioral therapy, exposure-based treatments, mindfulness practice, exercise. Each has its evidence base. Each has its limitations.
Selank fits an unusual niche. It is not a daily SSRI replacement — the chronic anxiety indication needs longer trial data than Russian sources provide. It is not a benzodiazepine substitute for severe panic — acute potency is lower. It is closer to a tool for what might be called "performance reactivity" — the moderate anxiety states that disrupt cognitive function, social interaction, and decision quality without rising to clinical diagnosis.
For this use case, the alternatives are limited. Beta-blockers (propranolol) address the somatic symptoms of performance anxiety but not the cognitive component. Buspirone has a slow onset and is best for chronic rather than acute use. Phenibut produces useful effects but carries dependence risk. Alcohol is the most common solution and the most damaging. Cannabis is variably effective and produces cognitive impairment.
Selank's positioning: reduces reactivity without sedation, without cognitive dulling, without dependence liability, with onset within 30-60 minutes of dosing. The trade-off is the regulatory status outside Russia, the sourcing risk, and the absence of large Western safety data.
Comparison to Benzodiazepines and Phenibut
The most useful comparisons for prospective users:
Versus benzodiazepines (alprazolam, lorazepam, clonazepam): benzodiazepines bind directly at the benzodiazepine site of the GABA-A receptor, producing rapid and powerful anxiolysis with sedation, cognitive impairment, and a real dependence and withdrawal liability. Long-term benzodiazepine use carries risks of tolerance, cognitive impairment, and withdrawal syndromes that can be severe and prolonged. Selank does not produce sedation, has no documented dependence in the Russian clinical record, and does not have a withdrawal syndrome on discontinuation. The trade-off: benzodiazepines have stronger acute anxiolysis. Selank has a cleaner long-term profile.
Versus phenibut (beta-phenyl-GABA): phenibut is a GABA-B receptor agonist with sedating, disinhibiting effects similar to alcohol at higher doses. Phenibut has a well-documented dependence liability, with withdrawal syndromes that include severe anxiety, insomnia, and in extreme cases psychosis. Tolerance develops rapidly. Selank's mechanism is distinct and the safety profile is fundamentally cleaner. Anyone considering phenibut for anxiety should consider selank as a safer alternative with a similar non-prescription accessibility.
Versus SSRIs: SSRIs operate through serotonin reuptake inhibition over weeks-to-months timescales. Selank operates more acutely (30-60 minutes to effect) and through a partially overlapping but distinct mechanism. Selank can be used acutely or as needed; SSRIs require chronic dosing. The conditions treated differ — SSRIs have evidence in major depression, OCD, and broader anxiety disorders; selank's clinical evidence is narrower (GAD, neurasthenia).
Versus alcohol: alcohol is the most common self-medication for anxiety, with well-known downsides including impaired sleep (sleep-deprivation-testosterone covers this), dependence liability, and metabolic consequences. Selank does not produce the sleep architecture damage that alcohol does, does not produce hangover effects, and does not have alcohol's broader health downsides. For users currently using alcohol as their primary anxiety tool, selank is worth evaluating as a substitute or partial substitute.
Dosing — Intranasal Specific Range
Standard selank dosing in Russian clinical use:
For anxiety disorders: 75-100 mcg per dose, 2-3 times daily, intranasal. Total daily dose of 250-450 mcg in most clinical protocols.
For acute use: 150-300 mcg single dose before anticipated stressor (presentation, examination, high-stakes interaction).
For continuous use: 75-150 mcg twice daily as maintenance.
The commercial Russian product is typically 0.15% nasal spray (1.5 mg/mL), with each spray delivering approximately 50-75 mcg. Anecdotal Western user protocols generally mirror the Russian clinical range, sometimes at the higher end (300-900 mcg/day) for resistant anxiety or for stacking with semax.
Onset: 20-40 minutes after intranasal dosing. Duration of acute effect: 3-5 hours. Multiple daily doses are needed for sustained effect.
Timing: selank does not interfere with sleep at standard doses. It can be dosed throughout the day including evening. Some users report mild sleep onset support when dosed before bed, though this is not a registered indication.
Cycle length: Russian clinical protocols often run 10-14 day courses for acute anxiety episodes and 30-60 day courses for chronic anxiety conditions. Anecdotal continuous use over months has not been associated with the dependence or tolerance issues seen with benzodiazepines, but long-term Western use data is essentially absent.
Stacking with Semax
The canonical Russian peptide stack: selank and semax. The logic is mechanistic complementarity.
Semax activates focus and cognitive load capacity. Selank reduces anxiety and stress reactivity. Together they support demanding cognitive performance under stress conditions — competitive exams, high-stakes presentations, sustained work under deadline pressure.
Typical stack protocol:
Morning: semax 300-600 mcg for focus Mid-day: selank 150 mcg if stress accumulation is a factor Pre-event: selank 300 mcg 30-45 minutes before high-anxiety performance situations Evening (if needed): selank 75-150 mcg for residual stress
Both peptides intranasal. No known pharmacokinetic interaction. Can be co-administered or separated by hours.
This stack is the closest the peptide world comes to a "performance under stress" combination with established mechanism. The executive-performance protocol approaches the same goal through different tools (sleep, caffeine-theanine-stack, cognitive training); the peptide stack is an option for users with specific high-anxiety performance contexts.
The combat-athlete protocol also has relevance here — competitive anxiety and performance under pressure benefit from the same mechanism that helps anxiety patients in clinical settings.
Selank is the closest thing in the peptide world to a non-sedating anxiolytic with a clinical track record. The track record is Russian, the regulatory recognition is Russian, and the Western user base is dosing a product the FDA has never reviewed.
The Immune and Antiviral Angle — Often Overlooked
The tuftsin lineage gives selank a side effect profile distinct from other anxiolytics: documented immune system effects.
Tuftsin's natural biological role is phagocyte activation and immune modulation. The peptide enhances macrophage function, supports natural killer cell activity, and modulates inflammatory cytokine balance. Selank inherits some of these properties, with Russian preclinical and clinical work documenting effects on immune function and antiviral activity.
The most studied antiviral application: respiratory viral infections. Russian work has reported reduced duration and severity of upper respiratory viral illness when selank is administered prophylactically or early in infection. The mechanism is plausibly mediated through the tuftsin-related immune modulation. The evidence is Russian-specific, methodologically limited, and not validated in Western trials.
The implication for users: selank may have peripheral immune effects that distinguish it from pure CNS-acting anxiolytics. This is generally framed positively (immune support), but it also means the peptide is not pharmacologically as "clean" as users sometimes assume. Anyone with autoimmune conditions, immunosuppression, or active infection should approach with awareness that the peptide has effects beyond the central nervous system.
The relevance for daily users: probably minor at typical doses. The immune effects in the literature are more pronounced at higher doses and during continuous use. For acute anxiety management at 75-300 mcg doses, the immune signal is unlikely to dominate the user experience.
Realistic Expectations
Selank is subtle compared to benzodiazepines and more reliable than over-the-counter anxiety supplements. The honest user experience:
Acute use before a stressor — measurable reduction in subjective anxiety, no cognitive dulling, no sedation. The effect is most apparent in users who would otherwise have substantial anticipatory anxiety.
Continuous use for generalized anxiety — gradual reduction in baseline reactivity over 1-2 weeks. Less pronounced acute effect, more pronounced cumulative effect.
Failure modes — some users report no clear effect. The peptide is not universally effective. Some users find the effect too subtle to be useful for severe anxiety. For these users, the combination with semax often produces a more noticeable subjective experience because the focus component is more felt than the anxiolytic component.
The peptide does not produce euphoria, does not produce disinhibition, and does not produce the social-lubricant effect of alcohol or benzodiazepines. Anyone seeking those effects will not find them in selank.
Tracking and Biomarkers
Useful tracking variables:
Subjective anxiety logs: rate anxiety on 0-10 scale at consistent times. Track over 14-30 days on selank versus baseline.
Sleep quality and architecture: selank does not typically disrupt sleep. If sleep changes occur (positive or negative), document them. The sleep-deprivation-testosterone framework applies — addressing sleep is foundational regardless of anxiolytic use.
Cognitive performance: working memory and verbal fluency at baseline and during use. Selank should not impair these; impairment would be a stop signal.
Biomarker context: cortisol-am is the most relevant single biomarker for anxiety load. Chronically elevated morning cortisol that normalizes during selank use is a meaningful objective signal. Hrv is a general autonomic balance marker — improved HRV during selank use is consistent with reduced sympathetic tone. Total-testosterone is not a primary endpoint but chronic anxiety suppresses testosterone, and addressing the anxiety can have downstream hormonal effects.
Stop signals: paradoxical mood worsening, irritability, new depressive symptoms, sleep disruption that does not resolve, allergic-type nasal reactions, any neurological symptom. Any of these — stop and consult a physician.
The Protocol
Source Verification
Russian pharmacy products are the most consistent supply. Research-chemical vendors require third-party purity testing. Verify the product is selank (not a related peptide or contaminated material).
Starting Dose
75-150 mcg intranasal, 2-3 times daily, for 7-14 days. Assess response.
Acute Use
300 mcg 30-45 minutes before anticipated stressor. Can be used as-needed without daily dosing if the use case is event-specific.
Continuous Use
75-150 mcg twice daily for ongoing anxiety. Can be sustained for 30-60 days based on Russian clinical patterns. Western long-term data is absent.
Stack Options
Semax 300-600 mcg in the morning for focus + selank distributed through the day for stress reactivity. The canonical Russian combination.
Concurrent Foundations
Address sleep first. Eight hours minimum. The sleep-deprivation-testosterone protocol applies. No peptide rescues chronic sleep debt.
Address alcohol. Daily alcohol use compounds anxiety and disrupts the sleep architecture that supports natural anxiety regulation.
Address training. Aerobic exercise has well-documented anxiolytic effects. Selank works better in a body that is moving regularly.
Stop Signals
Paradoxical mood change, new depressive symptoms, sleep disruption, neurological symptoms. Stop and consult a physician.
Disclosure
Inform your primary care physician of selank use. The peptide is not on standard medication interaction databases, and clinicians treating you for other conditions should know.
Reality Check
Selank is subtle. It is not a benzodiazepine replacement for severe panic. It is a useful tool for moderate anxiety and stress reactivity, particularly stacked with semax for performance contexts. The Russian clinical evidence is real but not Western-replicated.
Key Takeaways
- Selank is a Russian-developed tuftsin analog used clinically for anxiety, with the Zozulya 2008 trial showing efficacy comparable to medazepam without sedation or withdrawal.
- The mechanism includes GABA-A modulation, serotonergic effects, BDNF upregulation, and enkephalin system interactions — producing anxiolysis without cognitive dulling.
- Standard dosing is 75-300 mcg intranasal, 2-3 times daily, with the option of higher acute doses (300 mcg) before stressors.
- Selank stacks cleanly with semax — selank for anxiety, semax for focus — as the canonical Russian peptide combination for performance under stress.
- Selank is not FDA-approved or registered in most Western jurisdictions. Sourcing risk is the principal practical concern outside Russia; the safety record within Russian clinical use is favorable.
Want to know if your anxiety and stress reactivity are driven by sleep, cortisol, or something else? Take the PrimalPrime Stress Assessment to get a personalized baseline and protocol.